Arterra Bioscience (ARBS) Q4 2025 TU earnings summary

Executive summary

• Revenue for the year ended December 31, 2024, reached €4.2 million, up 28.21% year-over-year.

• Growth driven primarily by increased sales of cosmetic raw materials.

• Achieved results slightly exceeded management's expectations, with a positive outlook for early 2025.

Financial highlights

• Total revenue rose from €3.25 million in 2023 to €4.17 million in 2024, a 28.21% increase.

• Sales of cosmetic raw materials grew 33.67% year-over-year, from €2.63 million to €3.52 million.

• Service revenue increased by 5.09%, from €622,080 to €653,760.

Outlook and guidance

• Early 2025 signals indicate continued optimism for further growth.

• Management expects ongoing benefits from commercial development activities.